MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599043 | Name: Lividomycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lividomycin is a representative of the pseudo-tetrasaccharide group among the NEO-type AGAs.

Chemical Structure

Lividomycin
CAS#11111-23-2

Theoretical Analysis

MedKoo Cat#: 599043

Name: Lividomycin

CAS#: 11111-23-2

Chemical Formula: C29H55N5O18

Exact Mass: 761.3542

Molecular Weight: 761.77

Elemental Analysis: C, 45.72; H, 7.28; N, 9.19; O, 37.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lividomycin; LVM;
IUPAC/Chemical Name
(2R,3S,4S,5S,6R)-2-(((2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-4-hydroxytetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChi Key
DBLVDAUGBTYDFR-SWMBIRFSSA-N
InChi Code
InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1
SMILES Code
N[C@@H]1[C@@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CO)O2)[C@H](O[C@H]3[C@H](O)[C@H](O[C@@H]4[C@H](N)[C@@H](O)[C@H](O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)[C@H](CN)O4)[C@@H](CO)O3)[C@@H](O)[C@H](N)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 761.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Clausnitzer D, Piepersberg W, Wehmeier UF. The oxidoreductases LivQ and NeoQ are responsible for the different 6'-modifications in the aminoglycosides lividomycin and neomycin. J Appl Microbiol. 2011 Sep;111(3):642-51. doi: 10.1111/j.1365-2672.2011.05082.x. Epub 2011 Jul 12. PubMed PMID: 21689223. 2: Kobayashi F, Yamaguchi M, Mitsuhashi S. Activity of lividomycin against Pseudomonas aeruginosa: its inactivation by phosphorylation induced by resistant strains. Antimicrob Agents Chemother. 1972 Jan;1(1):17-21. PubMed PMID: 4207755; PubMed Central PMCID: PMC444159. 3: Mori T, Kyotani Y, Watanabe I, Oda T. Chemical conversion of lividomycin A into lividomycin B. J Antibiot (Tokyo). 1972 Feb;25(2):149-50. PubMed PMID: 5034809. 4: Yamaguchi M, Koshi T, Kobayashi F, Mitsuhashi S. Phosphorylation of lividomycin by Escherichia coli carrying an R factor. Antimicrob Agents Chemother. 1972 Sep;2(3):142-6. PubMed PMID: 4597704; PubMed Central PMCID: PMC444281. 5: Kondo H, Miwa T, Suhachiro M, Yokouchi S, Ando Y. [Clinical experiences of lividomycin on respiratory tract infections (author's transl)]. Jpn J Antibiot. 1975 Apr;28(2):149-54. Japanese. PubMed PMID: 1041282. 6: Yamamoto H, Kondo S, Maeda K, Umezawa H. Synthesis of lividomycin A 5''-phosphate, an enzymatically inactivated lividomycin A. J Antibiot (Tokyo). 1972 Aug;25(8):485-6. PubMed PMID: 4648492. 7: Takahashi R, Kato S. [Lividomycin therapy in intestinal infections with special reference to the combined use of lividomycin and AB-PC]. Kansenshogaku Zasshi. 1973 Aug;47(8):283-8. Japanese. PubMed PMID: 4202860. 8: Kuntzmann F, Weiss JM, Berthel M, Colonna JC, Conraux C, Reinhardt W, Brogard JM, Federspil P. [Ototoxicity of aminoglucosides. A case of deafness after lividomycin]. Nouv Presse Med. 1979 Apr 28;8(19):1604-5. French. PubMed PMID: 258790. 9: Yamaguchi M, Eda J, Kobayashi F, Mitsuhashi S. Mode of action of lividomycin on protein synthesis in Escherichia coli. Antimicrob Agents Chemother. 1973 Sep;4(3):380-2. PubMed PMID: 4586150; PubMed Central PMCID: PMC444562. 10: Tsukamura M. A preliminary trial of lividomycin in patients with pulmonary tuberculosis. Tubercle. 1972 Mar;53(1):43-6. PubMed PMID: 5038199. 11: Leroy A, Oksenhendler G, Fillastre JP, Humbert G. [Pharmacokinetics of lividomycin, aminkacin and sisomicin in patients with chronic renal insufficiency]. J Urol Nephrol (Paris). 1977 Sep;83(9):738-41. French. PubMed PMID: 243544. 12: Gomi J, Aoyagi T, Torikai K, Yamada Y, Fujino T. The fundamental studies on antituberculous activities of lividomycin. Kekkaku. 1971 Jul;46(7):265-9. PubMed PMID: 4329783. 13: Da Veiga C, Mezher J, Dumas P, Ennifar E. Isothermal Titration Calorimetry: Assisted Crystallization of RNA-Ligand Complexes. Methods Mol Biol. 2016;1320:127-43. doi: 10.1007/978-1-4939-2763-0_9. PubMed PMID: 26227041. 14: Leroy A, Humbert G, Oksenhendler G, Fillastre JP. Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients. J Antimicrob Chemother. 1976 Dec;2(4):373-81. PubMed PMID: 1052072. 15: Marmo E, Cazzola M, Brita G, Paciello C. [Experimental studies on the pharmacokinetics of lividomycin A]. Arch Monaldi. 1975 Jul-Aug;30(4):279-86. Italian. PubMed PMID: 1047629. 16: Yamaguchi M, Kobayashi F, Mitsuhashi S. Comparative studies on the activities of lividomycin 5''-phosphate and lividomycin on polypeptide synthesis directed by poly U in E. coli cell-free extracts. J Antibiot (Tokyo). 1973 Oct;26(10):602-5. PubMed PMID: 4599521. 17: Marengo PB, Chenoweth ME, Overturf GD, Wilkins J. Phosphorylation of kanamycin, lividomycin A, amd butirosin B by Providencia stuartii. Antimicrob Agents Chemother. 1974 Dec;6(6):821-4. PubMed PMID: 4455126; PubMed Central PMCID: PMC444743. 18: Tsukamura M, Mizuno S. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol. 1975 Jun;88(2):269-74. PubMed PMID: 50402. 19: Lato SM, Ellington AD. Screening chemical libraries for nucleic-acid-binding drugs by in vitro selection: a test case with lividomycin. Mol Divers. 1996 Oct;2(1-2):103-10. PubMed PMID: 9238640. 20: Tsukamura M. [Therapeutic effect of lividomycin on infections of the respiratory tract (author's transl)]. Jpn J Antibiot. 1975 Apr;28(2):143-8. Japanese. PubMed PMID: 807755.

View History

LL-BM 726

LL-BM 726

Dimetridazole HCl

Dimetridazole HCl

NMI-187

NMI-187

Diminazene dihydrocholoride

Diminazene dihydrocholoride

Merisoprol acetate Hg 197

Merisoprol acetate Hg 197

Toripristone

Toripristone